Just Like Last Year

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.

Friends,

Last year began with a big rally for cannabis stocks that left us quite skeptical. We warned in early February to go slow when things are hot. We were bullish longer-term, but the low-volume rally left us concerned.

This year, the NCV Global Cannabis Stock Index has rallied too, though not as strongly as last year’s start. Again, the volume is quite low. A year ago, when we warned about the low volume, we cited that only 7 of the cannabis names traded more than $5 million worth of stock on the first Friday of the year. This compared to 21 in 2022 and 21 in 2022. Well, today only 7 stocks exceeded $5 million in trading value.

The market sank on the first day with the overall stock market. For the week, the overall market fell sharply, while the GCSI rallied.  The GCSI gained 5.2%, while the S&P 500 lost 1.5%. Last year, when the cannabis stocks rallied in the first week, the S&P 500 did too.

The reason cannabis stocks jumped on Wednesday and Thursday seems silly to us. It related to an article that was published on Wednesday that discussed how the DEA is considering rescheduling cannabis. Old news!

The story remains the same in our view. The DEA may reschedule cannabis from Schedule 1 to Schedule 3. If that happens, then 280E taxation would by law go away. The news this week did not change the probability of this outcome. We continue to keep our fingers crossed, but we have no basis for concluding that this will happen or when it might happen.

We are cautious about this rally to begin 2024. It happened on very low volume. We will repeat what we said to conclude the letter a year ago: The lack of trading volume concerned us.

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:

Exclusives

To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.

Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer the Canadian Cannabis LP Index, the American Cannabis Operator Index and the Ancillary Cannabis Index.

View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks.

Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.

Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.

Sincerely,

Alan & Joel

Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email